Advanced Regenerative Medicines for Rare Diseases: A Review of Industry Sponsors Investment Motivations
Therapeutic Innovation & Regulatory Science · 2024
DOI: 10.1007/s43441-024-00690-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von Ubaka Ogbogu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Law, University of Alberta, Edmonton, Canada. uogbogu@ualberta.ca. Hauptthemen laut MEDLINE: Rare Diseases, Regenerative Medicine, Drug Industry, Motivation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stem Cell Network.
Abstract (Originalsprache)
Despite regulatory changes designed to stimulate investment in therapies for rare diseases, many of these conditions lack government-approved treatments. Advanced regenerative medicines, which are therapies and clinical interventions aimed at healing or replacing damaged or defective human cells, tissues, and organs, offer great promise for addressing many rare diseases. A major challenge facing advanced regenerative medicines for rare diseases is securing financial support to assist in bringing a therapy to market. This paper describes the factors cited by pharmaceutical industry players globally for sponsoring the development of advanced regenerative medicines for rare diseases. The paper examines the motivations of 53 sponsors that meet the latter criteria. The motivations behind investments were broadly similar amongst sponsors and map closely onto regulatory requirements for clinical development and marketing authorization of advanced therapeutic products, including the presence of accelerated or attenuated pathways for regulatory approval, use for indications with high unmet medical needs, and/or that have advantages over existing therapies, and robust preclinical data. Other factors include availability of investment incentives and opportunities for off-label use in the post-approval stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Law, University of Alberta, Edmonton, Canada. uogbogu@ualberta.ca.
- Alexander Holburn, Vancouver, B.C., Canada.
ORCID-Profile: Ubaka Ogbogu
Förderung
- Stem Cell Network
Zitieren
APA
Ogbogu, U., & Nel, A. (2024). Advanced Regenerative Medicines for Rare Diseases: A Review of Industry Sponsors Investment Motivations. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00690-x
Vancouver
Ogbogu U, Nel A. Advanced Regenerative Medicines for Rare Diseases: A Review of Industry Sponsors Investment Motivations. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00690-x
BibTeX
@article{Ogbogu2024,
author = {Ogbogu, Ubaka and Nel, Anja},
title = {Advanced Regenerative Medicines for Rare Diseases: A Review of Industry Sponsors Investment Motivations},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2024},
doi = {10.1007/s43441-024-00690-x}
}
EUVIMED